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oRIGINAL ARTICLE
Introduction: To compare the outcomes of two different multimo-
dality regimens involving neoadjuvant chemotherapy, extrapleural 
pneumonectomy (EPP) and adjuvant radiotherapy versus pleurec-
tomy/decortication (P/D), hyperthermic pleural lavage with povi-
done-iodine, and adjuvant chemotherapy in patients with malignant 
pleural mesothelioma.
Methods: Nonrandomized prospective study of patients treated 
by multimodality therapy and operated on between January 
2004 and June 2011. Second-line treatments were administered 
when appropriate. Survival and prognostic factors were analyzed 
by the Kaplan Meier method, log rank test, and Cox regression 
analysis.
Results: Twenty-five consecutive patients received neoadjuvant che-
motherapy, 22 underwent EPP, and 17 received adjuvant radiotherapy. 
over the same period, 54 consecutive patients underwent P/D and 
hyperthermic pleural lavage and received prophylactic radiotherapy 
and adjuvant chemotherapy. The 30-day mortality rate was 4.5% in 
the EPP group and nil in the P/D group. Fifteen patients (68%) in the 
EPP group and 15 (27.7%) in the P/D group experienced complica-
tions. There were no differences between the EPP and P/D groups for 
age, sex, histology, pathologic stage, and nodal status. Trimodality 
therapy was completed by 68% of the patients in the EPP group and 
100% in the P/D group. Survival was significantly better in the P/D 
group: median survival was 23 months versus 12.8 months, 2-year 
survival was 49% versus 18.2 %, and 5-year survival was 30.1% ver-
sus 9%, respectively (p = 0.004). At multivariate analysis, epithe-
lioid histology, P/D, and completeness of resection were independent 
prognostic factors.
Conclusions: In our experience, P/D, hyperthermic pleural lavage 
with povidone-iodine, and adjuvant chemotherapy were superior to 
neoadjuvant chemotherapy, EPP, and adjuvant radiotherapy.
Key Words: Malignant pleural mesothelioma, Pleurectomy, 
Extrapleural pneumonectomy.
(J Thorac Oncol. 2012;7: 737–743)
Malignant pleural mesothelioma (MPM) remains a major cause of death in patients exposed to asbestos.1 At 
present, there is no known curative treatment for MPM and 
the majority of patients are offered palliative chemothera-
py.2 Median survival following diagnosis is often less than 
12 months.2,3 However, patients with early-stage disease and 
good-performance status are suitable for multimodality ther-
apy involving surgery, radiotherapy, and chemotherapy.4,5
Extrapleural pneumonectomy (EPP) gained wide accep-
tance following the publications of Sugarbaker and Rusch 
showing prolonged survival in patients with epithelioid histol-
ogy.5,6 Large experiences have now been accumulated at some 
institutions offering chemotherapy, EPP, and adjuvant radio-
therapy, with 5-year survival rates over 40% in patients with 
favorable prognostic factors.7–9 Although EPP-related mor-
tality is now less than 8% in large-volume centers, less than 
60% of the patients complete trimodality treatment because of 
death or major complications.7–13 When patients relapse fol-
lowing EPP, they usually die within 3 months because of the 
lack of further effective treatment options.14
Pleurectomy/decortication (P/D) has long been used in 
patients with MPM. In 1976, Martini et al reported a median 
survival of 21 months following pleurectomy, adjuvant radio-
therapy, and systemic chemotherapy.15 More recently, similar 
outcomes have been reported in patients treated with P/D and 
adjuvant radiotherapy plus chemotherapy.16–18
Since 2004, we have offered EPP and P/D as part of our 
multimodality therapy program. Some patients were not suit-
able for EPP or refused to have EPP and we developed an alter-
native multimodality-therapy regimen for these patients based 
on P/D and hyperthermic pleural lavage followed by prophylac-
tic radiotherapy and adjuvant chemotherapy. This study aims to 
analyze the outcomes of patients treated consecutively at our 
institution with the two different multimodality regimens.
PATIENTS AND METHODS
Between January 2004 and June 2011, patients referred 
for multimodality therapy were offered either neodjuvant 
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chemotherapy, followed by EPP and adjuvant radiotherapy (54 
Gy) or P/D and hyperthermic pleural lavage with povidone-
iodine followed by prophylactic radiotherapy (21 Gy in three 
fractions) at 4 to 6 weeks, and adjuvant chemotherapy started 
at 6 to 8 weeks postoperatively. Recruitment was via a spe-
cialized multidisciplinary thoracic oncology clinic, involving 
thoracic surgeons, radiation oncologists, and medical oncolo-
gists. Histopathology and imaging review was undertaken for 
all patients. The choice of multimodality regimen was deter-
mined by a patient’s performance status, comorbidities, clinical 
tumor, node, metastasis (TNM) stage, histologic subtype, and 
the patient’s preference. Patients not wishing to undergo EPP 
or enroll into a trial offering EPP19 were offered the alternative 
treatment involving P/D and pleural lavage, prophylactic radio-
therapy, and adjuvant chemotherapy. All surgical procedures in 
this study were performed by the same surgeon (L.L.L.).
All patients had 18 fluorodeoxyglucose-positron-emis-
sion-tomography-computed tomography (PET-CT) performed 
preoperatively to exclude N3 disease or extrathoracic metasta-
ses. Previous talc pleurodesis was not regarded as a contrain-
dication to the performance of EPP or P/D. Mediastinoscopy 
was offered to all patients scheduled to have EPP to rule out 
N2 disease, as this was regarded as a contraindication to EPP 
in our center. However, nonbulky N2 disease was not regarded 
as a contraindication to P/D and mediastinoscopy was not rou-
tinely performed before P/D. only patients with performance 
status 0 to 1 were offered multimodality therapy at our institu-
tion. This was a nonrandomized study. The primary end point 
was survival. Secondary end points included mortality and 
treatment-related complications.
Neoadjuvant Chemotherapy Protocol  
(EPP Group)
All patients received neoadjuvant chemotherapy before 
EPP. Eleven patients received three cycles of induction che-
motherapy with cisplatin (80 mg/m2) and gemcitabine (1000 
mg/m2). Fourteen patients received three cycles of induction 
chemotherapy with cisplatin (80 mg/m2) and pemetrexed (500 
mg/m2). Repeat imaging showed potentially resectable disease 
in all patients.
Surgical Protocol for EPP and P/D Groups
EPP involved en-bloc resection of the affected lung, 
visceral and parietal pleurae, ipsilateral pericardium, ante-
rior mediastinal fat, and diaphragm. All procedures were 
performed through a large posterolateral thoracotomy (fifth 
and eighth interspace). The pericardium was replaced with 
a Polyglactin mesh (Vicryl, Ethicon, Johnson & Johnson 
Intl., St. Stevens Woluwe, Belgium) and the diaphragm was 
replaced with a Gore-Tex mesh (2-mm Dual Mesh, WL Gore 
and associates UK Ltd., Livingston, West Lothian, U.K.) in all 
patients. Systematic dissection of the mediastinal and internal 
mammary lymph nodes was routinely performed. All patients 
were staged according to the International Mesothelioma 
Interest Group staging system.
The goal in all patients undergoing P/D was to achieve 
maximal cytoreduction and a complete macroscopic resec-
tion. The approach was always a posterolateral thoracotomy 
through the fifth intercostal space. occasionally, a second-
access thoracotomy was made in the eighth interspace to help 
achieve complete resection of the tumor in the diaphragmatic 
recess or to resect the diaphragm. Extended resection to 
include the pericardium, lung, or diaphragm was undertaken 
as necessary. When the diaphragm was involved (deep mus-
cular invasion) it was resected and reconstructed using a large 
Gore-Tex mesh. Following extrapleural dissection, complete 
decortication of the lung was performed including the pulmo-
nary fissures down to the pulmonary hilum and pleural reflec-
tion. Lymphadenectomy of the internal mammary chains and 
mediastinal chains was routinely performed.
once the P/D had been completed, we performed a hyper-
thermic pleural lavage (40–41°C) using sterile water mixed 
with 10% povidone-iodine (Videne, Ecolab Ltd., Lotherton 
Way Gartforth, Leeds, U.K., dilution 1/10). In all patients, 5 
to 6 liters of water were used. The washout was allowed to 
bath in the pleural cavity for 5 minutes while the lung was 
being ventilated, and was then aspirated. This maneuver was 
repeated three times (total, 15 minutes).
Adjuvant Radiotherapy Post-EPP
The prescribed dose was 54 Gy in 30 fractions over 6 
weeks to the 100% isodose. For right-sided patients, it was not 
always possible to safely prescribe 54 Gy to the lower half of 
the field because of dose constraints to the liver. The minimum 
prescribed dose to the lower portion of right-sided volumes 
was 45 Gy. Radiotherapy was administered using a 6 MV lin-
ear accelerator and a three-dimensional conformal technique 
with multileaf collimation.
Prophylactic Radiotherapy Protocol Post-P/D
All patients were reviewed in the clinic at 4 to 5 weeks 
postoperatively and referred for prophylactic radiotherapy (21 
Gy in three daily fractions) on the thoracotomy, drain, and pre-
vious port sites according to Boutin’s protocol.20
Adjuvant Chemotherapy Protocol Post-P/D
Adjuvant chemotherapy was started after 6 to 8 weeks of 
P/D and consisted of a combination of gemcitabine (1000 mg/
m2) and cisplatin (80 mg/m2) before 2007 (n = 4), and peme-
trexed (500 mg/m2) and cisplatin (80 mg/m2) thereafter (n = 50).
The intent was to administer four to six cycles of chemother-
apy. Patients were followed up in the clinic regularly and had 
PET-CT arranged 6 months after completion of chemotherapy 
and then every 6 months to monitor response to treatment or 
disease progression. Those relapsing following a multimodality 
therapy were offered second-line treatment: a combination che-
motherapy with pemetrexed and cisplatin, single-agent vinorel-
bine, or single-agent Sorafenib as part of a phase-I trial.
Statistical Analysis
Continuous data are reported with medians and ranges, 
whereas categorical data are reported with counts and per-
centages. All potential prognostic indices were measured at 
the time of operation and evaluated as categorical variables. 
Survival was expressed from diagnosis. Survival and prog-
nostic factors were analyzed by the Kaplan Meier method, 
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log rank test, and Cox proportional hazards regression anal-
ysis. Hazard ratios and 95% confidence intervals were used 
to quantify the observed differences. Probability values less 
than 0.05 were considered statistically significant. All analy-




Twenty-five patients consented to have EPP. In three 
patients EPP was abandoned because of the extent of disease 
at the time of surgery (T4 including aortic invasion in two 
patients and multifocal chest-wall invasion in one patient). 
Eleven procedures were left-sided and 11 right-sided. one 
patient died of aortic rupture intraoperatively, making our 
30-day mortality rate 4.5%. Complications were experienced 
by 68% of the patients after EPP and are reported in Table 1. 
Median postoperative in-hospital stay was 14 days (range, 
8–60 d).
All three patients who suffered a bronchopleural fistula 
and empyema had an open-window thoracostomy performed 
9 to 28 weeks following EPP. Two of these patients did not 
receive adjuvant radiotherapy. one patient had received adju-
vant radiotherapy before suffering pleural empyema.
Seventeen patients (68%) received adjuvant radio-
therapy and completed the full multimodality treatment. 
Radiotherapy was started 8 to 12 weeks after EPP. Five 
patients did not receive radiotherapy because one died 
intraoperatively, two presented a bronchopleural fistula 
with empyema, one progressed before having radiotherapy 
developing contralateral pulmonary metastases, and one 
developed a late septicemia 2 months after surgery. one 
patient with bronchopleural fistula and empyema is still 
alive and underwent an open-window thoracostomy fol-
lowed by reconstruction 1 year later. Survival for these 
five patients was: 0, 2, 31, 2.9, and 55 months (mean, 
14.6; median, 2.9 months), respectively. Complications of 
radiotherapy included: grade-1 esophagitis (n = 6, 35.3%), 
radiation hepatitis (n = 3, 17.6%), radiation pneumonitis 
(n = 2, 11.8%), fatal pulmonary embolus (n = 1, 5.9%), 
fatal pneumonia (n = 1, 5.9%), grade-3 thombocytopenia (n 
= 1, 5.9%), herpes zoster transverse myelitis (n = 1, 5.9%), 
and late constrictive pericarditis (n = 1, 5.9%).
In EPP patients, death was mainly related to disease pro-
gression (n = 17, 81%) with patients diagnosed with intratho-
racic relapse (52%), peritoneal relapse (40%), or relapse at 
distant sites (16%). Some patients had relapse in multiple 
sites. The median follow-up of 22 patients who underwent 
EPP was 12.9 months (0–55). Five patients were followed up 
for more than 2 years. Two patients are still alive at 55 and 51 
months postoperatively. Twenty patients have died at the time 
of the analysis (october 2011).
P/D Group
Sixty-one patients had P/D performed. Three meso-
thelioma patients referred for empyema and trapped lung 
following talc pleurodesis were excluded retrospectively 
because of the potential impact of empyema on the natural 
history of malignant mesothelioma. They did not undergo 
P/D with a curative intent. Chemotherapy was not adminis-
tered to these patients. Three other patients were excluded 
as they had received intrapleural gene therapy before P/D as 
part of a phase-I trial at another center. A total of 54 patients 
had P/D followed by prophylactic radiotherapy and adjuvant 
chemotherapy.
Thirty-three procedures were right-sided, 21 left-
sided. Thirty-one patients (57.4 %) underwent macroscopic 
complete resection whereas 23 underwent R2 resection 
(42.6 %). Extended resections included diaphragm (n = 5), 
lobectomy (n = 3), segmentectomy (n = 2), and pericardiec-
tomy (n = 2). The 30-day mortality was nil. Fifteen patients 
(27.7%) experienced postoperative complications after P/D; 
these findings are reported in Table 1. We did not observe 
wound infections, pleural empyema, or mesh infection in 
this series.
Fifty-two patients (96.3 %) received the planned four 
to six cycles of adjuvant chemotherapy and completed the 
full multimodality-therapy regimen. Two patients received 
two cycles of adjuvant chemotherapy only together with 
prophylactic radiotherapy, because of poor tolerance of 
treatment.
Fifteen patients received second-line treatment or are 
receiving second-line treatment at last follow-up. Second-line 
treatment includes pemetrexed and cisplatin (n = 3), single-
agent vinorelbine (n = 7) or single-agent sorafenib as part of 
a phase-I trial (n = 5). one patient diagnosed with very focal 
relapse at 1 year following P/D was treated with cyberknife 
radiosurgery and remains disease-free at 51 months. of note, 
none of our patients were diagnosed with chest-wall tumor 
seeding at follow-up.
At the time of analysis, 28 of 54 patients were alive and 
26 patients had died of disease progression. Survival is pre-
sented in Figs. 1 through 3. The median follow-up of patients 
who underwent P/D was 15.7 (5–67.5) and 15 patients had a 
follow-up of 2 years or more.
The median interval between diagnosis and start of the 
neoadjuvant treatment in EPP group was 4 months, and the 






Arrhythmia 7 (28) 2 (3.7)
Reoperation for bleeding 2 (8) —
Bronchopleural fistula/empyema 3 (12) —
Persistent air leak — 10 (18.5)
Pulmonary embolus 1 (4) —
Pneumonia 1 (4) —
Chylothorax — 4 (7.4)
Vocal cord palsy 1 (4) —
Horner’s syndrome 1 (4) —
Late septicemia 1 (4) —
ARDS 1 (4) 1 (1.8)
EPP, extrapleural pneumonectomy; P/D, pleurectomy/decortication; ARDS, acute 
respiratory distress syndrome.
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median interval between diagnosis and the P/D was 3 months. 
Most patients underwent video-assisted thoracoscopic surgery 
and talc pleurodesis before P/D.
Table 2 presents patients’ characteristics and shows 
there was no significant difference between the two groups of 
patients in terms of age, sex, histology, nodal status, and TNM 
stage. There was no patient older than 70 years in the EPP 
group, whereas 9 out of 54 patients were older than 70 in the 
P/D group (p = 0.04).
There was a statistically significant difference in sur-
vival between patients having EPP and those having P/D, in 
favor of P/D (p = 0.004): median survival was 23 months ver-
sus 12.8 months, 1-year survival was 81.9% versus 54.5%, 
2-year survival was 49% versus 18.2%, and 5-year survival 
was 30.1% versus 9%, respectively. When comparing by his-
tology, we found that patients with epithelioid tumor had a 
longer survival with P/D than with EPP (p = 0.018): median 
survival was 28.9 months versus 12.8 months, 1-year survival 
was 91.2% versus 57.1%, 2-year survival was 54% versus 
28.6%, and 5-year survival was 42% versus 14.3%, respec-
tively. Patients with nonepithelioid histology had a marginally 
better survival after P/D than after EPP (p = 0.07): median 
survival was 18.3 months versus 8.8 months, 1-year survival 
was 62.3% versus 50%, 2-year survival was 38% versus 0%, 
and 5-year survival was 9.5% versus 0%, respectively.
Complete macroscopic resection was associated with 
longer survival in patients having P/D (p = 0.02): median sur-
vival was 31 months versus 16.6 months, 1-year survival was 
89% versus 72.7%, 2-year survival was 63.8% versus 28.5%, 
and 5-year survival was 38.7% versus 19%, respectively. 
Patients having P/D and complete macroscopic resection 
had a significantly longer survival than patients having EPP 
(p = 0.0007): median survival was 31 months versus 12.8 
months, 1-year survival was 89% versus 54.5%, 2-year sur-
vival was 63.8% versus 18.2%, and 5-year survival was 38.7% 
versus 9%, respectively.
P/D provided a significant survival advantage over 
EPP in patients with N0 disease (p = 0.04): median sur-
vival was 28.9 months versus 12.9 months, 1-year survival 
was 73% versus 60%, 2-year survival was 54.8 % versus 
10%, and 5-year survival was 18.3% versus 0%, respec-
tively. However, the difference did not reach statistical 
significance in patients with N1 to N2 disease (p = 0.07): 
median survival was 23.4 months versus 8.8 months, 1-year 
survival was 85.6% versus 50%, 2-year survival was 47.2% 
versus 25%, and 5-year survival was 33.8% versus 16.6%, 
respectively.
When comparing by stage, we found that patients 
with early-stage disease (stages I and II) and patients with 
advanced-stage disease (III and IV) had a significantly longer 
survival in the P/D group than in the EPP group (p = 0.004 and 
p = 0.048, respectively).
Multivariate analysis showed that the type of surgi-
cal procedure (P/D versus EPP), histology, and complete 
macroscopic resection were independent prognostic factors 
(Table 3).
DISCUSSION
The role of radical surgery, especially EPP, in MPM 
remains controversial.11 Retrospective series and recent phase-II 
trials showed median survivals of 10 to 29 months following 
EPP in highly selected patients demonstrating favorable prog-
nostic factors.5–10 In most series, the information was acquired 
FIGURE 1. Overall survival 
following EPP versus P/D. EPP, 
extrapleural pneumonectomy; P/D, 
pleurectomy/decortication; CI, 
confidence interval.
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retrospectively and data were not collected with an “intention 
to treat”. of note, in two recent prospective trials, fewer than 
70% of the patients could complete the full multimodality 
treatment.7,21 Although mortality has fallen consistently over 
time from 33% in 1976 to less than 8% now at most special-
ist centers,,8–10,12,19 the morbidity associated with EPP remains 
high with serious complications developing in more than 50% 
of patients.12,22 Adjuvant radiotherapy can generate significant 
complications and mortality as well.13 Recently, the results of 
the randomized mesothelioma and radical surgery (MARS) 
feasibility trial have been published and suggest that EPP offers 
no survival benefit and possibly harms patients.19 However, data 
were acquired in a limited number of patients and the trial was 
not powered to assess the superiority of EPP over no EPP.19
Recent studies suggest that P/D is an interesting option 
in patients with MPM and early-stage disease.18,23,24 Mortality 
is low and complications are less common than in EPP.23 In 
a recent analysis of 663 patients operated on at 3 different 
institutions over a 16-year period, Flores et al23 found that 
P/D was associated with a significantly better survival than 
EPP. However, the reasons were probably multifactorial and 
subject to selection bias. Indications, surgical technique, and 
perioperative management did probably vary over time and 
were possibly different at different institutions. Moreover, the 
use of adjuvant radiotherapy and chemotherapy varied over 
the time period considered. Altogether, the level of evidence 
provided in this study is weak.
In this setting, it seemed interesting to look at our recent 
personal experience with two different multimodality regi-
mens involving EPP and P/D. The advantage of doing so is 
that the surgical cohorts are very homogeneous. Thus, all sur-
gical procedures were performed by the same thoracic sur-
geon in the same hospital. We used similar radiotherapy and 
chemotherapy protocols in all patients.
our patients did not receive radical radiotherapy after 
P/D, but only prophylactic radiotherapy to avoid the risk of 
radiation pneumonitis.17 There is no evidence that radiother-
apy more than 45 Gy improves local control or survival after 
P/D. Conversely, there is some evidence that radical radiother-
apy after EPP improves local control;,5–9 therefore our patients 
received radical radiotherapy after EPP.
Chemotherapy regimens differ between the EPP and P/D 
groups. As in other studies, we administered chemotherapy as 
a neoadjuvant treatment before EPP.7 However, it made more 
sense to administer chemotherapy as an adjuvant treatment 
after P/D to clear any residual microscopic or macroscopic 
disease. We recognize that the number of chemotherapy cycles 
received (3 versus 4-6) could have influenced survival in the 
responding patients.
All patients were recruited through the same clinic and 
discussed by the same group of thoracic specialists using 
the same staging methods and selection criteria, entered 
prospectively into our mesothelioma database. Like any sin-
gle-institution series, our series suffers limitations compared 
to a large multicenter study, even though all patients were 
selected by the same multidisciplinary team and were oper-
ated by the same surgeon, reducing possible selection and 
treatment bias.
our analysis shows that the EPP and P/D groups could 
be matched for age, sex, histology, TNM stage, and nodal 
FIGURE 2. Overall survival fol-
lowing EPP versus P/D in patients 
with epithelioid histology. EPP, 
extrapleural pneumonectomy; P/D, 
pleurectomy/decortication; MPM, 
malignant pleural mesothelioma; 
CI, confidence interval.
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status. Although patients were not randomized for EPP or P/D, 
the analysis of outcomes should provide some form of evi-
dence regarding the superiority of one multimodality regime 
over the other.
At multivariate analysis, P/D, epithelioid histology 
and complete resection were independent prognostic factors, 
whereas TNM staging and nodal status were not. This is 
probably related to the small number of patients in the study. 
Larger series have previously shown the impact of stage and 
nodal disease on survival.5,9
our mortality rate for EPP (4.5%) and complications 
rate are comparable to those obtained at large-volume institu-
tions.21 our mortality rate for P/D (nil) and complications rate 
compare favorably to those obtained at other large-volume 
institutions.16–18 Therefore, we cannot be criticized for offering 
suboptimal surgery, a criticism made to the randomized meso-
thelioma and radical surgery trialists.25 The vast majority of 
our patients completed trimodality therapy, reflecting the good 
acceptance and tolerability of our multimodality regimens.
our goal, when performing EPP or P/D, was always to 
achieve complete macroscopic resection (R0–R1). Despite our 
efforts, this was not always possible and in some patients having 
P/D, we decided to accept an incomplete resection (R2) rather 
FIGURE 3. Impact of complete 
macroscopic resection on survival. 
There is no statistical difference in 
terms of survival between incom-
plete macroscopic resection in P/D 
patients and in complete macro-
scopic resection in EPP patients  
(p = 0.2). EPP, extrapleural pneu-
monectomy; P/D, pleurectomy/
decortication; CI, confidence 
interval.
TABLE 2. Patient Characteristics







62 (52–68) 62.5 (45–74) 0.5
 < 70 22 (100) 45 (83.3)
 ≥ 70 0 9 (16.7)
Sex 0.7
 Male 20 (90.9) 47 (87)
 Female 2 (8.1) 7 (13)
Histology 0.8
 Epithelioid 14 (63.6) 36 (66.7)
 Nonepithelioid 8 (36.4) 18 (33.3)
Nodal status 0.18
 N0 12 (54.5) 38 (70.4)
 N1/N2 10 (45.5) 16 (29.6)
Staging 0.07
 Stage I 2 (9) 6 (11)
 Stage II 1 (4.5) 14 (26)
 Stage III 12 (54.5) 27 (50)
 Stage IV 7 (32) 7 (13)
EPP, extrapleural pneumonectomy; P/D, pleurectomy/decortication.
TABLE 3. Multivariate Analysis of the Characteristics 
Significant at Univariate Analysis
Characteristic HR (95% CI) p Value
Histology (Nonepithelioid vs. 
Epithelioid)
2.15 (1.15–4.0) 0.015
Resection (R0/R1 vs. R2) 2.5 (1.1–5.7) 0.025
operation (P/D vs. EPP) 3.6 (1.7–7.4) 0.001
Nodal involvement (N0 vs. N1/N2) 1.2 (0.6–2.3) 0.5
Pathological stage (Stages I and II 
vs. III and IV)
0.9 (0.4–2) 0.7
HR, hazard ratio; CI, confidence interval; EPP, extrapleural pneumonectomy; P/D, 
pleurectomy/decortication.
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than perform EPP. Interestingly, in our experience patients hav-
ing incomplete macroscopic resection with P/D (R2) had a sur-
vival similar to those having macroscopic complete resection 
with EPP. Survival rates were significantly better in patients 
having P/D and complete macroscopic resection (Fig. 3). 
Therefore, we suggest performing maximal cytoreduction, but 
sparing the diaphragm (and pericardium) to minimize intra-
peritoneal seeding (intrapericardial seeding) in patients who 
cannot have R0/R1 resection. We do not believe that EPP adds 
any survival advantage in this group of patients.
The patterns of relapse following P/D have been well 
described by others and were similar in our series.14 Most 
patients relapsed in the ipsilateral hemithorax, progressed in 
the mediastinum, contralateral hemithorax, and even devel-
oped systemic metastases. of note, when patients had disease 
progression after P/D, most of them were still able to receive 
second-line chemotherapy or targeted therapy as opposed to 
patients having had EPP who were often too unwell to receive 
any active treatment. In our experience, peritoneal seed-
ing was exceptionally diagnosed after P/D, but commonly 
observed after EPP. Finally, patients who develop pneumonia 
or pulmonary embolus following EPP are very likely to die, 
whereas they are more likely to survive if this happens after 
P/D. Although not often raised, this issue should always be 
considered in patients receiving multimodality therapy for 
pleural mesothelioma.26
Considering that EPP resulted in higher mortality and 
morbidity than P/D, that P/D resulted in significantly better 
survival in our experience as in others’, we propose that P/D 
becomes the standard surgical procedure offered as part of 
multimodality therapy in MPM.
This has been our position since 2008 and others have 
shared the same opinion for several years.24,27 As a randomized 
trial of EPP versus P/D is unlikely to be performed,28 we support 
the idea of a large multicenter randomized trial of multimodality 
therapy involving P/D versus no-P/D in patients with MPM. The 
manner in which surgeons perform P/D needs to be standardized 
first and following this, a randomized study could evaluate the 
impact of P/D versus no-P/D on survival and quality of life.
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